ArticleCurrent microbiology2026
Construction of an Oral Vaccine Based on Multiple Antigens of African Swine Fever Virus Displayed on the Surface of Bacillus Subtilis Spores and Study of its Immune Effect in Rats.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In this study, we constructed an oral vaccine by expressing fusion antigens of African swine fever virus (ASFV) on the surface of Bacillus subtilis spores and explored its immunogenicity. Fusion proteins were designed, and recombinant strains that could stably express target proteins on the spore surface were successfully constructed. After oral immunization of rats, the spleen index and the levels of ASFV-specific IgG, interleukin-2, and interferon-γ were markedly increased, indicating effective activation of humoral and cellular immunity. This study established a reliable spore surface display system. The recombinant spores triggered favorable immune responses in vivo, providing an experimental foundation for the development of novel ASFV oral vaccines.
Indexed as
Identifiers
42400677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.